{"id":540961,"date":"2021-09-22T08:08:11","date_gmt":"2021-09-22T12:08:11","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/harmony-biosciences-announces-winners-of-patients-at-the-heart-and-progress-at-the-heart-on-third-annual-world-narcolepsy-day\/"},"modified":"2021-09-22T08:08:11","modified_gmt":"2021-09-22T12:08:11","slug":"harmony-biosciences-announces-winners-of-patients-at-the-heart-and-progress-at-the-heart-on-third-annual-world-narcolepsy-day","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/harmony-biosciences-announces-winners-of-patients-at-the-heart-and-progress-at-the-heart-on-third-annual-world-narcolepsy-day\/","title":{"rendered":"Harmony Biosciences Announces Winners of Patients at the Heart and Progress at the Heart on Third Annual World Narcolepsy Day"},"content":{"rendered":"
\n

Eight organizations awarded with more than $180,000 in patient-centric funding for the narcolepsy and rare disease communities<\/h2>\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n PLYMOUTH MEETING, Pa.<\/span>, Sept. 22, 2021<\/span> \/PRNewswire\/ — Harmony Biosciences Holdings, Inc. (“Harmony”)\u00a0(Nasdaq: HRMY), a pharmaceutical company dedicated to\u00a0developing and commercializing innovative therapies for patients with rare neurological diseases, today announced winners of the Patient at the Heart and Progress at the Heart programs in honor of the third annual World Narcolepsy Day. <\/p>\n

\n

\n
\n \"Harmony
\n <\/a>\n <\/p>\n<\/p><\/div>\n

The Patients at the Heart program was created in 2019, and awards funds to not-for-profit organizations working to support and address the challenges of people living with sleep disorders and rare diseases who experience excessive daytime sleepiness (EDS). Initiated in 2021, Progress at the Heart supports innovative programs that address disparities, injustice, and inequities in the rare disease and sleep disorder community.<\/p>\n

“We are so inspired by the diverse and inventive programs submitted for this year’s Patients and Progress at the Heart programs,” said Cate McCanless, SVP, Corporate Affairs and Public Policy. “Our goal is to improve the lives of people living with sleep disorders and their families, and we hope by supporting these cutting-edge programs, we can make a positive difference for these communities.” <\/p>\n

The company chose to announce the winners on World Narcolepsy Day, a day dedicated to raising awareness for this sleep disorder globally. The first Patients at the Heart program awarded $65,000<\/span> to four organizations, which was increased to $74,000<\/span> in 2020. Now, combined with the Progress at the Heart recipients, total funds awarded in 2021 increased to over $180,000<\/span> awarded to eight organizations across the United States<\/span>. <\/p>\n

The following organizations, by category, were chosen as the 2021 Patients at the Heart<\/b> recipients:<\/p>\n

\n Narcolepsy<\/b>\n <\/p>\n